{"disease":{"id":"mucopolysaccharidosis-mps-ii","name":"Mucopolysaccharidosis, MPS-II","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"elaprase","indication_name":"Mucopolysaccharidosis, MPS-II","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Elaprase","company_name":"Shire","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":9,"revenue":null,"mechanism":null},{"drug_id":"vestronidase-alfa","indication_name":"Mucopolysaccharidosis, MPS-VII","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mepsevii","generic_name":"VESTRONIDASE ALFA","company_name":"Ultragenyx Pharm Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Lysosomal beta Glucuronidase [EPC]","quality_score":10,"revenue":null,"mechanism":"Mepsevii works by replacing the deficient enzyme beta-glucuronidase in patients with MPS-VII."},{"drug_id":"idursulfase","indication_name":"Mucopolysaccharidosis, MPS-II","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elaprase","generic_name":"IDURSULFASE","company_name":"Takeda","drug_phase":"marketed","molecular_target":"","drug_class":"Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC]","quality_score":50,"revenue":null,"mechanism":"Elaprase works by replacing the deficient enzyme iduronate-2-sulfatase in the body."},{"drug_id":"vestronidase-alfa-vjbk","indication_name":"Mucopolysaccharidosis, MPS-VII","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MEPSEVII","generic_name":"VESTRONIDASE ALFA-VJBK","company_name":"ULTRAGENYX PHARM INC","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"mepsevii","indication_name":"Mucopolysaccharidosis, MPS-VII","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mepsevii","company_name":"Ultragenyx Pharmaceutical Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":5,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00630747","title":"Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT00607386","title":"Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT03041324","title":"Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Sangamo Therapeutics","has_results":true},{"nct_id":"NCT04571970","title":"RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"REGENXBIO Inc.","has_results":false},{"nct_id":"NCT02618512","title":"A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}